Functional 358Ala Allele Impairs Classical IL-6 Receptor Signaling and Influences Risk of Diverse Inflammatory Diseases

English version České info

Inflammation, which is directly regulated by interleukin-6 (IL-6) signaling, is implicated in the etiology of several chronic diseases. Although a common, non-synonymous variant in the IL-6 receptor gene (IL6R Asp358Ala; rs2228145 A>C) is associated with the risk of several common diseases, with the 358Ala allele conferring protection from coronary heart disease (CHD), rheumatoid arthritis (RA), atrial fibrillation (AF), abdominal aortic aneurysm (AAA), and increased susceptibility to asthma, the variant's effect on IL-6 signaling is not known. Here we provide evidence for the association of this non-synonymous variant with the risk of type 1 diabetes (T1D) in two independent populations and confirm that rs2228145 is the major determinant of the concentration of circulating soluble IL-6R (sIL-6R) levels (34.6% increase in sIL-6R per copy of the minor allele 358Ala; rs2228145 [C]). To further investigate the molecular mechanism of this variant, we analyzed expression of IL-6R in peripheral blood mononuclear cells (PBMCs) in 128 volunteers from the Cambridge BioResource. We demonstrate that, although 358Ala increases transcription of the soluble IL6R isoform (P = 8.3×10⁻²²) and not the membrane-bound isoform, 358Ala reduces surface expression of IL-6R on CD4+ T cells and monocytes (up to 28% reduction per allele; P≤5.6×10⁻²²). Importantly, reduced expression of membrane-bound IL-6R resulted in impaired IL-6 responsiveness, as measured by decreased phosphorylation of the transcription factors STAT3 and STAT1 following stimulation with IL-6 (P≤5.2×10⁻⁷). Our findings elucidate the regulation of IL-6 signaling by IL-6R, which is causally relevant to several complex diseases, identify mechanisms for new approaches to target the IL-6/IL-6R axis, and anticipate differences in treatment response to IL-6 therapies based on this common IL6R variant.

Vyšlo v časopise: Functional 358Ala Allele Impairs Classical IL-6 Receptor Signaling and Influences Risk of Diverse Inflammatory Diseases. PLoS Genet 9(4): e32767. doi:10.1371/journal.pgen.1003444
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003444

Souhrn

Zdroje

1. Van SnickJ (1990) Interleukin-6: An Overview. Annual Review of Immunology 8: 253–278.

2. NeurathMF, FinottoS (2011) IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine & Growth Factor Reviews 22: 83–89.

3. KallenK-J (2002) The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1592: 323–343.

4. ChalarisA, GarbersC, RabeB, Rose-JohnS, SchellerJ (2011) The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer. European Journal of Cell Biology 90: 484–494.

5. IL6R Genetics Consortium Emerging Risk Factors Collaboration (2012) Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. The Lancet 379: 1205–1213.

6. The Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium (2012) The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. The Lancet 379: 1214–1224.

7. DeloukasP, KanoniS, WillenborgC, FarrallM, AssimesTL, et al. (2013) Large-scale association analysis identifies new risk loci for coronary artery disease. Nature Genetics 45: 25–33.

8. EyreS, BowesJ, DiogoD, LeeA, BartonA, et al. (2012) High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 44: 1336–1340.

9. SchnabelRB, KerrKF, LubitzSA, AlkylbekovaEL, MarcusGM, et al. (2011) Large-Scale Candidate Gene Analysis in Whites and African Americans Identifies IL6R Polymorphism in Relation to Atrial Fibrillation/Clinical Perspective. Circulation: Cardiovascular Genetics 4: 557–564.

10. HarrisonSC, SmithAJP, JonesGT, SwerdlowDI, RampuriR, et al. (2012) Interleukin-6 receptor pathways in abdominal aortic aneurysm. European Heart Journal

11. FerreiraMAR, MathesonMC, DuffyDL, MarksGB, HuiJ, et al. (2011) Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. The Lancet 378: 1006–1014.

12. ReichD, PattersonN, RameshV, De JagerPL, McDonaldGJ, et al. (2007) Admixture Mapping of an Allele Affecting Interleukin 6 Soluble Receptor and Interleukin 6 Levels. The American Journal of Human Genetics 80: 716–726.

13. CortesA, BrownMA (2011) Promise and pitfalls of the Immunochip. Arthritis Research & Therapy 13: 101.

14. LustJA, DonovanKA, KlineMP, GreippPR, KyleRA, et al. (1992) Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 4: 96–100.

15. MullbergJ, OberthurW, LottspeichF, MehlE, DittrichE, et al. (1994) The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. The Journal of Immunology 152: 4958–4968.

16. BrisoEM, DienzO, RinconM (2008) Cutting Edge: Soluble IL-6R Is Produced by IL-6R Ectodomain Shedding in Activated CD4 T Cells. The Journal of Immunology 180: 7102–7106.

17. StephensOW, ZhangQ, QuP, ZhouY, ChavanS, et al. (2012) An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. Blood 119: 503–512.

18. SchneiderA, LongSA, CerosalettiK, NiCT, SamuelsP, et al. (2013) In Active Relapsing-Remitting Multiple Sclerosis, Effector T Cell Resistance to Adaptive Tregs Involves IL-6-Mediated Signaling. Science Translational Medicine 5: 170ra115.

19. BettelliE, KornT, KuchrooVK (2007) Th17: the third member of the effector T cell trilogy. Current Opinion in Immunology 19: 652–657.

20. KornT, BettelliE, OukkaM, KuchrooVK (2009) IL-17 and Th17 Cells. Annual Review of Immunology 27: 485–517.

21. GoodmanWA, YoungAB, McCormickTS, CooperKD, LevineAD (2011) Stat3 Phosphorylation Mediates Resistance of Primary Human T Cells to Regulatory T Cell Suppression. The Journal of Immunology 186: 3336–3345.

22. YaoZ, KannoY, KerenyiM, StephensG, DurantL, et al. (2007) Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 109: 4368–4375.

23. LaurenceA, AmarnathS, MariottiJ, Kim YongC, FoleyJ, et al. (2012) STAT3 Transcription Factor Promotes Instability of nTreg Cells and Limits Generation of iTreg Cells during Acute Murine Graft-versus-Host Disease. Immunity 37: 209–222.

24. LittmanDR, RudenskyAY (2010) Th17 and Regulatory T Cells in Mediating and Restraining Inflammation. Cell 140: 845–858.

25. DaneshJ, KaptogeS, MannAG, SarwarN, WoodA, et al. (2008) Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review. PLoS Med 5: e78 doi:10.1371/journal.pmed.0050078.

26. SchnabelRB, LarsonMG, YamamotoJF, KathiresanS, RongJ, et al. (2009) Relation of Multiple Inflammatory Biomarkers to Incident Atrial Fibrillation. The American journal of cardiology 104: 92–96.

27. NaitzaS, PorcuE, SteriM, TaubDD, MulasA, et al. (2012) A Genome-Wide Association Scan on the Levels of Markers of Inflammation in Sardinians Reveals Associations That Underpin Its Complex Regulation. PLoS Genet 8: e1002480 doi:10.1371/journal.pgen.1002480.

28. HeinrichPC, BehrmannI, Müller-NewenG, SchaperF, GraeveL (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochemical Journal 334: 297–314.

29. RidkerPM, PareG, ParkerA, ZeeRYL, DanikJS, et al. (2008) Loci Related to Metabolic-Syndrome Pathways Including LEPR,HNF1A, IL6R, and GCKR Associate with Plasma C-Reactive Protein: The Women's Genome Health Study. The American Journal of Human Genetics 82: 1185–1192.

30. DanikJS, ParéG, ChasmanDI, ZeeRYL, KwiatkowskiDJ, et al. (2009) Novel Loci, Including Those Related to Crohn Disease, Psoriasis, and Inflammation, Identified in a Genome-Wide Association Study of Fibrinogen in 17 686 Women/CLINICAL PERSPECTIVE. Circulation: Cardiovascular Genetics 2: 134–141.

31. WasselCL, LangeLA, KeatingBJ, TaylorKC, JohnsonAD, et al. (2011) Association of genomic loci from a cardiovascular gene SNP array with fibrinogen levels in European Americans and African-Americans from six cohort studies: the Candidate Gene Association Resource (CARe). Blood 117: 268–275.

32. GarbersC, JännerN, ChalarisA, MossML, FlossDM, et al. (2011) Species Specificity of ADAM10 and ADAM17 Proteins in Interleukin-6 (IL-6) Trans-signaling and Novel Role of ADAM10 in Inducible IL-6 Receptor Shedding. Journal of Biological Chemistry 286: 14804–14811.

33. BradshawEM, RaddassiK, ElyamanW, OrbanT, GottliebPA, et al. (2009) Monocytes from Patients with Type 1 Diabetes Spontaneously Secrete Proinflammatory Cytokines Inducing Th17 Cells. The Journal of Immunology 183: 4432–4439.

34. Navarro-MillánI, SinghJA, CurtisJR (2012) Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor. Clinical Therapeutics 34: 788–802.e783.

35. DoganciA, EigenbrodT, KrugN, De SanctisGT, HausdingM, et al. (2005) The IL-6R α chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. The Journal of Clinical Investigation 115: 313–325.

36. HawkinsGA, RobinsonMB, HastieAT, LiX, LiH, et al. (2012) The IL6R variation Asp358Ala is a potential modifier of lung function in subjects with asthma. Journal of Allergy and Clinical Immunology

37. RidkerPM (2009) Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). Journal of Thrombosis and Haemostasis 7: 332–339.

38. RidkerPM, ThurenT, ZalewskiA, LibbyP (2011) Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). American Heart Journal 162: 597–605.

39. O'DonoghueML, BraunwaldE, WhiteHD, SerruysP, StegPG, et al. (2011) Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. American Heart Journal 162: 613–619.e611.

40. NichollsSJ, CavenderMA, KasteleinJJP, SchwartzG, WatersDD, et al. (2012) Inhibition of secretory phospholipase A 2 in patients with acute coronary syndromes: Rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovascular Drugs and Therapy 26: 71–75.

41. SymmonsDPM, GabrielSE (2011) Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 7: 399–408.

42. KahlenbergJM, KaplanMJ (2012) Mechanisms of Premature Atherosclerosis in Rheumatoid Arthritis and Lupus. Annual Review of Medicine

43. OrchardTJ, CostacouT, KretowskiA, NestoRW (2006) Type 1 Diabetes and Coronary Artery Disease. Diabetes Care 29: 2528–2538.

44. EckelRH, EisenbarthGS (2012) Autoimmune Diabetes Inflames the Heart. Science Translational Medicine 4: 138fs118.

45. TanakaT, NarazakiM, KishimotoT (2011) Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Letters 585: 3699–3709.

46. JonesSA, SchellerJ, Rose-JohnS (2011) Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. The Journal of Clinical Investigation 121: 3375–3383.

47. HowsonJMM, StevensH, SmythDJ, WalkerNM, ChandlerKA, et al. (2011) Evidence That HLA Class I and II Associations With Type 1 Diabetes, Autoantibodies to GAD and Autoantibodies to IA-2, Are Distinct. Diabetes 60: 2635–2644.

48. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661–678.

49. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nature Genetics 39: 1329–1337.

50. SwaffordAD-E, HowsonJMM, DavisonLJ, WallaceC, SmythDJ, et al. (2011) An Allele of IKZF1 (Ikaros) Conferring Susceptibility to Childhood Acute Lymphoblastic Leukemia Protects Against Type 1 Diabetes. Diabetes 60: 1041–1044.

51. PfafflMW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.

52. TreeTIM, RoepBO, PeakmanM (2004) Enhancing the Sensitivity of Assays to Detect T Cell Reactivity: The Effect of Cell Separation and Cryopreservation Media. Annals of the New York Academy of Sciences 1037: 26–32.

53. DendrouCA, PlagnolV, FungE, YangJHM, DownesK, et al. (2009) Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nature Genetics 41: 1011–1015.

54. PruimRJ, WelchRP, SannaS, TeslovichTM, ChinesPS, et al. (2010) LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26: 2336–2337.

55. CordellHJ, BarrattBJ, ClaytonDG (2004) Case/pseudocontrol analysis in genetic association studies: A unified framework for detection of genotype and haplotype associations, gene-gene and gene-environment interactions, and parent-of-origin effects. Genetic Epidemiology 26: 167–185.